Free Trial
→ The tiny chipmaker set to supply Musk 5 billion chips (From Brownstone Research) (Ad)tc pixel Free SBFMW Stock Alerts

Sunshine Biopharma (SBFMW) Competitors

Sunshine Biopharma logo
$0.02 0.00 (0.00%)
As of 11:24 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

SBFMW vs. AIMDW, ALVOW, ARAV, ACABW, and BFRIW

Should you buy Sunshine Biopharma stock or one of its competitors? MarketBeat compares Sunshine Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sunshine Biopharma include Ainos (AIMDW), Alvotech (ALVOW), Aravive (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), and Biofrontera (BFRIW). These companies are all part of the "pharmaceutical products" industry.

How does Sunshine Biopharma compare to Ainos?

Sunshine Biopharma (NASDAQ:SBFMW) and Ainos (NASDAQ:AIMDW) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.

Company Net Margins Return on Equity Return on Assets
Sunshine BiopharmaN/A N/A N/A
Ainos N/A N/A N/A

In the previous week, Sunshine Biopharma and Sunshine Biopharma both had 2 articles in the media. Sunshine Biopharma's average media sentiment score of 1.45 beat Ainos' score of 0.93 indicating that Sunshine Biopharma is being referred to more favorably in the media.

Company Overall Sentiment
Sunshine Biopharma Positive
Ainos Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sunshine Biopharma$35.49MN/AN/AN/AN/A
Ainos$18.11KN/AN/AN/AN/A

Summary

Sunshine Biopharma beats Ainos on 2 of the 2 factors compared between the two stocks.

How does Sunshine Biopharma compare to Alvotech?

Alvotech (NASDAQ:ALVOW) and Sunshine Biopharma (NASDAQ:SBFMW) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk, media sentiment and valuation.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alvotech$586.32MN/AN/AN/AN/A
Sunshine Biopharma$35.49MN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
AlvotechN/A N/A N/A
Sunshine Biopharma N/A N/A N/A

In the previous week, Sunshine Biopharma had 1 more articles in the media than Alvotech. MarketBeat recorded 2 mentions for Sunshine Biopharma and 1 mentions for Alvotech. Alvotech's average media sentiment score of 1.89 beat Sunshine Biopharma's score of 1.45 indicating that Alvotech is being referred to more favorably in the media.

Company Overall Sentiment
Alvotech Very Positive
Sunshine Biopharma Positive

Summary

Alvotech beats Sunshine Biopharma on 2 of the 3 factors compared between the two stocks.

How does Sunshine Biopharma compare to Aravive?

Aravive (NASDAQ:ARAV) and Sunshine Biopharma (NASDAQ:SBFMW) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

35.8% of Aravive shares are held by institutional investors. 60.4% of Aravive shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Sunshine Biopharma had 2 more articles in the media than Aravive. MarketBeat recorded 2 mentions for Sunshine Biopharma and 0 mentions for Aravive. Sunshine Biopharma's average media sentiment score of 1.45 beat Aravive's score of 0.00 indicating that Sunshine Biopharma is being referred to more favorably in the news media.

Company Overall Sentiment
Aravive Neutral
Sunshine Biopharma Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AraviveN/AN/AN/A-$0.90N/A
Sunshine Biopharma$35.49MN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
AraviveN/A N/A N/A
Sunshine Biopharma N/A N/A N/A

Summary

Sunshine Biopharma beats Aravive on 3 of the 5 factors compared between the two stocks.

How does Sunshine Biopharma compare to Atlantic Coastal Acquisition Corp. II?

Sunshine Biopharma (NASDAQ:SBFMW) and Atlantic Coastal Acquisition Corp. II (NASDAQ:ACABW) are both pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

Company Net Margins Return on Equity Return on Assets
Sunshine BiopharmaN/A N/A N/A
Atlantic Coastal Acquisition Corp. II N/A N/A N/A

In the previous week, Sunshine Biopharma had 2 more articles in the media than Atlantic Coastal Acquisition Corp. II. MarketBeat recorded 2 mentions for Sunshine Biopharma and 0 mentions for Atlantic Coastal Acquisition Corp. II. Sunshine Biopharma's average media sentiment score of 1.45 beat Atlantic Coastal Acquisition Corp. II's score of 0.00 indicating that Sunshine Biopharma is being referred to more favorably in the media.

Company Overall Sentiment
Sunshine Biopharma Positive
Atlantic Coastal Acquisition Corp. II Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sunshine Biopharma$35.49MN/AN/AN/AN/A
Atlantic Coastal Acquisition Corp. IIN/AN/AN/AN/AN/A

Summary

Sunshine Biopharma beats Atlantic Coastal Acquisition Corp. II on 3 of the 3 factors compared between the two stocks.

How does Sunshine Biopharma compare to Biofrontera?

Sunshine Biopharma (NASDAQ:SBFMW) and Biofrontera (NASDAQ:BFRIW) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sunshine Biopharma$35.49MN/AN/AN/AN/A
Biofrontera$43.20MN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
Sunshine BiopharmaN/A N/A N/A
Biofrontera N/A N/A N/A

In the previous week, Sunshine Biopharma had 1 more articles in the media than Biofrontera. MarketBeat recorded 2 mentions for Sunshine Biopharma and 1 mentions for Biofrontera. Biofrontera's average media sentiment score of 1.87 beat Sunshine Biopharma's score of 1.45 indicating that Biofrontera is being referred to more favorably in the news media.

Company Overall Sentiment
Sunshine Biopharma Positive
Biofrontera Very Positive

Summary

Biofrontera beats Sunshine Biopharma on 2 of the 3 factors compared between the two stocks.

Get Sunshine Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for SBFMW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SBFMW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SBFMW vs. The Competition

Export
MetricSunshine BiopharmaDrug Manufacturers IndustryMedical SectorNASDAQ Exchange
Market CapN/A$2.38B$6.47B$11.81B
Dividend YieldN/A2.95%2.67%5.55%
P/E RatioN/A4.8624.5923.77
Price / SalesN/A1,641.04501.97106.22
Price / CashN/A10.1842.3656.09
Price / BookN/A10.1810.386.79
Net IncomeN/A$20.27B$3.56B$337.26M
7 Day PerformanceN/A0.68%-0.95%-0.71%
1 Month PerformanceN/A7.42%1.15%1.78%
1 Year PerformanceN/A17.85%20.15%23.57%

Sunshine Biopharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SBFMW
Sunshine Biopharma
N/A$0.03
flat		N/A-90.7%$0.00$35.49MN/A3
AIMDW
Ainos
N/A$0.11
-14.3%		N/A+32.4%$0.00$18.11KN/A40
ALVOW
Alvotech
N/A$0.24
-7.7%		N/A-88.5%$0.00$586.32MN/A4
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20
ACABW
Atlantic Coastal Acquisition Corp. II
N/A$0.00
flat		N/AN/A$0.00N/AN/A15

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SBFMW) was last updated on 6/10/2026 by MarketBeat.com Staff.
From Our Partners
He Called NVIDIA at $1.10 – Now He Says, “SELL”
The analyst who called NVIDIA at $1.10 now says sell. According to Alexander Green, Chief Investment Strategis...
The Oxford Club | Sponsoredtc pixel
One hidden supplier shipped 5 billion parts to SpaceX
Most investors are focused on the historic $1.75 trillion SpaceX IPO expected around June 30. But there's a le...
Weiss Ratings | Sponsoredtc pixel
The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...
Banyan Hill Publishing | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
This IPO Could Make SpaceX Look Small (Read before June 16)
A red-hot AI startup just filed to go public - already valued at nearly $1 trillion. Wall Street veteran Marc ...
Chaikin Analytics | Sponsoredtc pixel
The part that convinced me Joel is legit
Most trading gurus cite big win rates but won't let you verify them. Joel Peterson is different - his trade pl...
Crypto Swap Profits | Sponsoredtc pixel
How to claim a stake in SpaceX before the June 12 IPO
SpaceX is expected to go public on June 12 - and for the first time, everyday investors may have a way in befo...
Brownstone Research | Sponsoredtc pixel
In 30 days, you'll wish you'd read this email
A small power equipment company with $1.5 billion in orders is flying under the radar - but not for long. When...
Behind the Markets | Sponsoredtc pixel